VERRICA PHARMACEUTICALS INC.

(VRCA)
  Report
Real-time Estimate Cboe BZX  -  10:05 2022-08-10 am EDT
3.235 USD   -0.46%
08/01Verrica Pharmaceuticals Receives $8 Million Milestone Payment From Torii Pharmaceutical After Phase 3 Viral Skin Disease Trial Gets Underway
MT
08/01Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan
GL
08/01Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
3.17(c) 3.38(c) 3.42(c) 3.25(c) 3.32 Last
83 723 98 403 76 862 76 802 6 204 Volume
+1.60% +6.62% +1.18% -4.97% +2.15% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1,08 M - -
Net income 2022 -36,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,77x
Yield 2022 -
Sales 2023 9,54 M - -
Net income 2023 -46,5 M - -
Net Debt 2023 - - -
P/E ratio 2023 -2,77x
Yield 2023 -
Capitalization 134 M 134 M -
Capi. / Sales 2022 123x
Capi. / Sales 2023 14,0x
Nbr of Employees 38
Free-Float 44,8%
More Financials
Company
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. The Company's lead product candidate, VP-102, is a drug-device combination of its topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. It... 
Sector
Pharmaceuticals
Calendar
08/10Earnings Release
More about the company
Ratings of Verrica Pharmaceuticals Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about VERRICA PHARMACEUTICALS INC.
08/01Verrica Pharmaceuticals Receives $8 Million Milestone Payment From Torii Pharmaceutical..
MT
08/01Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of..
GL
08/01Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of..
AQ
07/20BERGER MONTAGUE INVESTIGATES SECURIT : VRCA) - VERRICA PHARMACEUTICALS, INC. - Lead Plaint..
PR
07/13VERRICA PHARMACEUTICALS INC. : Other Events (form 8-K)
AQ
07/13Verrica Pharmaceuticals Inc. Voluntarily Repays Full Debt Outstanding Under the Mezzani..
CI
07/05INSIDER BUY : Verrica Pharmaceuticals
MT
07/01VERRICA PHARMACEUTICALS : Announces Proposed Public Offering of Common Stock - Form 8-K
PU
07/01VERRICA PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Other Events, F..
AQ
06/30VERRICA PHARMACEUTICALS, INC. COMPAN : Berger Montague Investigates Securities Fraud Alleg..
PR
06/30Verrica Pharmaceuticals Prices $25.2 Million Common Stock Offering
MT
06/29Verrica Announces Pricing of Public Offering of Common Stock
GL
06/29VERRICA PHARMACEUTICALS : Company Presentation
PU
06/29Verrica Pharmaceuticals Plans Common Stock Offering; Shares Plunge After-Hours
MT
06/29Verrica Announces Proposed Public Offering of Common Stock
GL
More news
News in other languages on VERRICA PHARMACEUTICALS INC.
08/01Verrica Pharmaceuticals reçoit un paiement d'étape de 8 millions de dollars de Torii Ph..
07/05ACHATS D'INITIÉS : Verrica Pharmaceuticals
06/30Verrica Pharmaceuticals lance une offre d'actions ordinaires pour un montant de 25,2 mi..
06/29Verrica Pharmaceuticals prévoit de proposer des actions ordinaires ; les actions plonge..
05/25MISE À JOUR SECTORIELLE : Les actions du secteur de la santé terminent presque inchangées
More news
Analyst Recommendations on VERRICA PHARMACEUTICALS INC.
More recommendations
Chart VERRICA PHARMACEUTICALS INC.
Duration : Period :
Verrica Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERRICA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 3,25 $
Average target price 10,25 $
Spread / Average Target 215%
EPS Revisions
Managers and Directors
Ted White President, Chief Executive Officer & Director
Terry Kohler Chief Financial & Accounting Officer
Paul B. Manning Chairman
Gary Goldenberg Chief Medical Officer
Eugene Scavola Executive Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
VERRICA PHARMACEUTICALS INC.-64.52%134
JOHNSON & JOHNSON-0.52%447 486
ELI LILLY AND COMPANY9.70%287 428
PFIZER, INC.-16.05%278 132
ROCHE HOLDING AG-16.68%273 741
ABBVIE INC.3.65%248 135